Director, University of Pittsburgh Medical Center (UPMC) Primary Care Precision Medicine Center
Co-Director, HUB Core: Integrating Special Populations and Community Partners Core
Clinical and Translational Science Institute (CTSI)
Institute for Precision Medicine
University of Pittsburgh
Director, UC Irvine Program in Medical
Education for the Latino Community
Associate Dean, School of Medicine
University of California, Irvine
Intermountain Medical Group
Salt Lake City, Utah
This activity is an informative and engaging presentation about blood-based multi-cancer early detection MCED screening in the primary care setting. Drs. Massart, Vega, and Whittington will provide key data related to current gaps in cancer surveillance, the science and data behind MCEDs, and information on how to implement MCED screening into practice.
The educational design of this activity addresses the needs of both primary care and specialist clinicians, including OB/GYN, geriatrics, and oncology.
Upon completion of this activity, participants will be better prepared to:
- Discuss the benefits, limitations, and potential harms of current cancer-screening recommendations and protocols
- Describe how cell-free DNA (cfDNA) can be used for the early detection of multiple cancer types
- Evaluate recent clinical data on available and emerging noninvasive multi-cancer screening tests and their utility in early cancer detection
- Design a practical protocol for integration of patient counseling and multi-cancer screening into workflow protocols in the primary care setting
PHYSICIAN ACCREDITATION STATEMENT
Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
PHYSICIAN CONTINUING MEDICAL EDUCATION
Integritas designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.
FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.
DISCLOSURES OF CONFLICTS OF INTEREST
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Mylynda B. Massart, MD, PhD Speakers Bureau: GRAIL
Charles P. Vega, MD, FAAFP Consulting Fees: Boehringer Ingelheim International GmbH, GlaxoSmithKline plc.
Richard A. Whittington, MD No financial relationships to disclose
The Integritas Communications planners and managers have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.